Diese Arbeit bestätigt Sturzangst als Einflussfaktor auf Stürze bei IPS-Patienten.
Als neue Information findet sich in dieser Arbeit eine Assoziation von links-temporalen WML mit dem Vorkommen von Stürzen. Diese kann durch Beeinflussung von Gedächtnis, Navigationsfähigkeit, Orientierung, auditiver Verarbeitung und Angstkonditionierung erklärt werden, da diese Fähigkeiten in diesem Hirnareal ‚durchgeführt‘ werden und zumindest für einen Teil dieser Fähigkeiten Hinweise für eine Lateralisierung bestehen. Diese Arbeit kann somit als Basis für weitere und möglicherweise spezifischere Arbeiten auf dem Gebiet der Sturzerfassung und -analyse bei IPS dienen.
50 5 Tabellenverzeichnis
Tabelle 1: Visuelle Bewertung der WML nach der SCHELTENS-Skala,
übersetzt von Scheltens et al.64 ... 11 Tabelle 2: Visuelle Bewertung der WML nach der WAHLUND-Skala, übersetzt von Wahlund et al.67 ... 14 Tabelle 3: Ein- und Ausschlusskriterien der ABC-PD-Studie ... 20 Tabelle 4: Demographische, klinische und radiologische Daten der gesamten Kohorte ... 33 Tabelle 5: Einfluss der einzelnen Faktoren auf das Vorkommen der Stürze .... 35 Tabelle 6: Im Regressionsmodell analysierte Faktoren ... 37 Tabelle 7: Einfluss der Faktoren Alter, MoCA-Score, BDI-II-Score, Sturzangst, MDS-UPDRS-III-Score, SCHELTENS-Skala-Gesamtscore und WAHLUND-Skala-rechts-links-Differenz-Betrag auf das Vorkommen der Stürze ... 38 Tabelle 8: Einfluss der Faktoren WAHLUND-Skala-links-temporal-Subscore, MoCA-Score, BDI-II-Score, Sturzangst, Alter, MDS-UPDRS-III-Score auf das Vorkommen von Stürzen ... 40 Tabelle 9: Einfluss der Faktoren WAHLUND-Skala-links-frontal-Subscore,
MoCA-Score, BDI-II-Score, Alter und MDS-UPDRS-III-Score auf das
Vorkommen von Stürzen ... 41 Tabelle 10: Einfluss der Faktoren WAHLUND-Skala-rechts-frontal-Subscore, MoCA-Score, BDI-II-Score, Alter und MDS-UPDRS-III-Score auf das
Vorkommen von Stürzen ... 42
51 6 Anhangsverzeichnis
Anhang 1: Einwilligungserklärung mit Entbindung von der Schweigepflicht für MRT-Aufnahmen
52 7 Literaturverzeichnis
1. Bischoff A. [Prevent accidental falls!]. MMW Fortschr Med.
2015;157(14):18-22. doi:10.1007/s15006-015-3398-2.
2. Evans D, Pester J, Vera L, Jeanmonod D, Jeanmonod R. Elderly fall patients triaged to the trauma bay: age, injury patterns, and mortality risk.
Am J Emerg Med. 2015;33(11):1635-1638.
doi:10.1016/j.ajem.2015.07.044.
3. Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E.
Risk Factors for Falls in Community-dwelling Older People. Epidemiology.
2010;21(5):658-668. doi:10.1097/EDE.0b013e3181e89905.
4. Latt MD, Lord SR, Morris JGL, Fung VSC. Clinical and physiological assessments for elucidating falls risk in Parkinson’s disease. Mov Disord.
2009;24(9):1280-1289. doi:10.1002/mds.22561.
5. Muraki S, Akune T, Oka H, et al. Physical performance, bone and joint diseases, and incidence of falls in Japanese men and women: a longitudinal cohort study. Osteoporos Int. 2013;24(2):459-466.
doi:10.1007/s00198-012-1967-0.
6. Jansen S, Frewen J, Finucane C, de Rooij SE, van der Velde N, Kenny RA. AF is associated with self-reported syncope and falls in a general population cohort. Age Ageing. 2015;44(4):598-603.
doi:10.1093/ageing/afv017.
7. Critchley RJ, Khan SK, Yarnall AJ, Parker MJ, Deehan DJ. Occurrence, management and outcomes of hip fractures in patients with Parkinson’s disease. Br Med Bull. 2015;115(1):135-142. doi:10.1093/bmb/ldv029.
8. Greenberg MR, Kane BG, Totten VY, et al. Injury due to mechanical falls:
future directions in gender-specific surveillance, screening, and interventions in emergency department patients. Acad Emerg Med.
2014;21(12):1380-1385. doi:10.1111/acem.12523.
9. Stevens JA, Sogolow ED. Gender differences for non-fatal unintentional fall related injuries among older adults. Inj Prev. 2005;11(2):115-119.
doi:10.1136/ip.2004.005835.
10. Oman D, Reed D, Ferrara A. Do elderly women have more physical disability than men do? Am J Epidemiol. 1999;150(8):834-842.
http://www.ncbi.nlm.nih.gov/pubmed/10522654. Accessed May 7, 2016.
11. Eggermont LHP, Penninx BWJH, Jones RN, Leveille SG. Depressive symptoms, chronic pain, and falls in older community-dwelling adults: the MOBILIZE Boston Study. J Am Geriatr Soc. 2012;60(2):230-237.
doi:10.1111/j.1532-5415.2011.03829.x.
12. Biderman A, Cwikel J, Fried A V, Galinsky D. Depression and falls among community dwelling elderly people: a search for common risk factors. J Epidemiol Community Health. 2002;56(8):631-636.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1732215&tool=
pmcentrez&rendertype=abstract. Accessed May 7, 2016.
13. Turcu A, Toubin S, Mourey F, D’Athis P, Manckoundia P, Pfitzenmeyer P.
Falls and depression in older people. Gerontology. 2004;50(5):303-308.
doi:10.1159/000079128.
14. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for
53
preventing falls in older people living in the community. Cochrane database Syst Rev. 2012;(9):CD007146.
doi:10.1002/14651858.CD007146.pub3.
15. Williams LJ, Pasco JA, Stuart AL, et al. Psychiatric disorders,
psychotropic medication use and falls among women: an observational study. BMC Psychiatry. 2015;15:75. doi:10.1186/s12888-015-0439-4.
16. Delbaere K, Close JCT, Brodaty H, Sachdev P, Lord SR. Determinants of disparities between perceived and physiological risk of falling among elderly people: cohort study. BMJ. 2010;341:c4165.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2930273&tool=
pmcentrez&rendertype=abstract. Accessed May 16, 2016.
17. Bloem BR, Steijns JAG, Smits-Engelsman BC. An update on falls. Curr Opin Neurol. 2003;16(1):15-26.
doi:10.1097/01.wco.0000053580.70044.70.
18. Koller WC, Glatt S, Vetere-Overfield B, Hassanein R. Falls and Parkinson’s disease. Clin Neuropharmacol. 1989;12(2):98-105.
http://www.ncbi.nlm.nih.gov/pubmed/2720700. Accessed March 24, 2016.
19. Muangpaisan W, Suwanpatoomlerd S, Srinonprasert V,
Sutipornpalangkul W, Wongprikron A, Assantchai P. Causes and course of falls resulting in hip fracture among elderly Thai patients. J Med Assoc Thai. 2015;98(3):298-305.
http://www.ncbi.nlm.nih.gov/pubmed/25920301. Accessed May 7, 2016.
20. Wendel-Vos GCW, Schuit AJ, Feskens EJM, et al. Physical activity and stroke. A meta-analysis of observational data. Int J Epidemiol.
2004;33(4):787-798. doi:10.1093/ije/dyh168.
21. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med. 2002;347(10):716-725. doi:10.1056/NEJMoa021067.
22. Verdelho A, Madureira S, Ferro JM, et al. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. Stroke.
2012;43(12):3331-3335. doi:10.1161/STROKEAHA.112.661793.
23. Stenhagen M, Ekström H, Nordell E, Elmståhl S. Accidental falls, health-related quality of life and life satisfaction: a prospective study of the general elderly population. Arch Gerontol Geriatr. 2013;58(1):95-100.
doi:10.1016/j.archger.2013.07.006.
24. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223-36; discussion 222. doi:10.1176/jnp.14.2.223.
25. Kalia L V, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896-912. doi:10.1016/S0140-6736(14)61393-3.
26. Beitz JM. Parkinson’s disease: a review. Front Biosci (Schol Ed).
2014;6:65-74. http://www.ncbi.nlm.nih.gov/pubmed/24389262. Accessed September 28, 2015.
27. Hacke W. Neurologie. 14. Heidelberg: Springer-Verlag; 2016.
28. Inzelberg R, Samuels Y, Azizi E, et al. Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. Neurol Genet.
2016;2(3):e70. doi:10.1212/NXG.0000000000000070.
29. Martin ER, Scott WK, Nance MA, et al. Association of single-nucleotide
54
polymorphisms of the tau gene with late-onset Parkinson disease. JAMA.
2001;286(18):2245-2250. http://www.ncbi.nlm.nih.gov/pubmed/11710889.
Accessed June 7, 2016.
30. Yu R, Guo J, Wang Y, et al. The single nucleotide polymorphism Rs12817488 is associated with Parkinson’s disease in the Chinese population. J Clin Neurosci. 2015;22(6):1002-1004.
doi:10.1016/j.jocn.2014.11.024.
31. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med. 1998;339(15):1044-1053. doi:10.1056/NEJM199810083391506.
32. Böcker W., Denk H., Heitz Ph. U., Höfler H.K., Kreipe H. MH. Pathologie.
5. München: Urban-Fischer; 2012.
33. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein
aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27(6):1405-1410.
doi:10.1523/JNEUROSCI.4564-06.2007.
34. Kalia L V, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol.
2013;73(2):155-169. doi:10.1002/ana.23746.
35. Del Tredici K, Braak H. Review: Sporadic Parkinson’s disease:
development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol. 2016;42(1):33-50. doi:10.1111/nan.12298.
36. Goedert M. NEURODEGENERATION. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015;349(6248):1255555.
doi:10.1126/science.1255555.
37. van Uem J, Marinus J, Canning C, et al. Health-related quality of life in patients with Parkinson’s disease - a systematic review based on the ICF model. Neurosci Biobehav Rev. 2015;61:26-34.
doi:10.1016/j.neubiorev.2015.11.014.
38. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-1601.
doi:10.1002/mds.26424.
39. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality.
Neurology. 1967;17(5):427-442.
http://www.ncbi.nlm.nih.gov/pubmed/6067254. Accessed January 8, 2015.
40. Maetzler W, Mancini M, Liepelt-Scarfone I, et al. Impaired trunk stability in individuals at high risk for Parkinson’s disease. PLoS One.
2012;7(3):e32240. doi:10.1371/journal.pone.0032240.
41. Maetzler W, Hausdorff JM. Motor signs in the prodromal phase of Parkinson’s disease. Mov Disord. 2012;27(5):627-633.
doi:10.1002/mds.24973.
42. Hiorth YH, Larsen JP, Lode K, Pedersen KF. Natural history of falls in a population-based cohort of patients with Parkinson’s disease: an 8-year prospective study. Parkinsonism Relat Disord. 2014;20(10):1059-1064.
doi:10.1016/j.parkreldis.2014.06.023.
43. Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson’s disease: frequency, impact and identifying
55
factors. J Neurol. 2005;252(11):1310-1315. doi:10.1007/s00415-005-0855-3.
44. Kerr GK, Worringham CJ, Cole MH, Lacherez PF, Wood JM, Silburn PA.
Predictors of future falls in Parkinson disease. Neurology.
2010;75(2):116-124. doi:10.1212/WNL.0b013e3181e7b688.
45. Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002;72(6):721-725.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1737913&tool=
pmcentrez&rendertype=abstract. Accessed March 22, 2016.
46. Gray P, Hildebrand K. Fall risk factors in Parkinson’s disease. J Neurosci Nurs. 2000;32(4):222-228.
http://www.ncbi.nlm.nih.gov/pubmed/10994536. Accessed May 7, 2016.
47. Fahn S, Elton R, UPDRS Development Committee. Unified Parkinsons Disease Rating Scale. In: Recent Developments in Parkinsons Disease.
2nd ed. Florham Park, NJ; 1987:153–163.
48. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.
doi:10.1136/jnnp.2007.131045.
49. Paul SS, Sherrington C, Canning CG, Fung VSC, Close JCT, Lord SR.
The relative contribution of physical and cognitive fall risk factors in people with Parkinson’s disease: a large prospective cohort study.
Neurorehabil Neural Repair. 2014;28(3):282-290.
doi:10.1177/1545968313508470.
50. Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ.
Impaired attention predicts falling in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(2):110-115. doi:10.1016/j.parkreldis.2008.03.010.
51. Heinzel S, Maechtel M, Hasmann SE, et al. Motor dual-tasking deficits predict falls in Parkinson’s disease: A prospective study. Parkinsonism Relat Disord. 2016;26:73-77. doi:10.1016/j.parkreldis.2016.03.007.
52. Benzinger P, Rapp K, Maetzler W, et al. Risk for femoral fractures in Parkinson’s disease patients with and without severe functional impairment. PLoS One. 2014;9(5):e97073.
doi:10.1371/journal.pone.0097073.
53. Bloem BR, Munneke M, Carpenter MG, Allum JHJ. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003;61(7):1023; author reply 1023-4.
http://www.ncbi.nlm.nih.gov/pubmed/14557594. Accessed May 7, 2016.
54. Blahak C, Bäzner H. Gangstörungen und Stürze bei älteren Patienten mit zerebraler Mikroangiopathie – Klinische Präsentation, Klassifikation, Diagnostik und Therapie. Aktuelle Neurol. 2014;41(2):107-115.
doi:10.1055/s-0034-1369835.
55. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol.
1987;44(1):21-23. http://www.ncbi.nlm.nih.gov/pubmed/3800716.
Accessed February 18, 2016.
56. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701. doi:10.1016/S1474-4422(10)70104-6.
56
57. Awad IA, Spetzler RF, Hodak JA, Awad CA, Carey R. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. I. Correlation with age and cerebrovascular risk factors. Stroke.
1986;17(6):1084-1089. http://www.ncbi.nlm.nih.gov/pubmed/3810705.
Accessed March 10, 2016.
58. Bots ML, van Swieten JC, Breteler MM, et al. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet (London, England). 1993;341(8855):1232-1237.
http://www.ncbi.nlm.nih.gov/pubmed/8098390. Accessed February 8, 2016.
59. Longstreth WT, Arnold AM, Beauchamp NJ, et al. Incidence,
manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke. 2005;36(1):56-61.
doi:10.1161/01.STR.0000149625.99732.69.
60. Longstreth WT, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27(8):1274-1282.
http://www.ncbi.nlm.nih.gov/pubmed/8711786. Accessed February 20, 2016.
61. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MMB. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke.
2008;39(10):2712-2719. doi:10.1161/STROKEAHA.107.513176.
62. Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology
correlations. J Neurol Neurosurg Psychiatry. 2011;82(2):126-135.
doi:10.1136/jnnp.2009.204685.
63. van Straaten ECW, Fazekas F, Rostrup E, et al. Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke. 2006;37(3):836-840.
doi:10.1161/01.STR.0000202585.26325.74.
64. Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993;114(1):7-12.
http://www.ncbi.nlm.nih.gov/pubmed/8433101. Accessed February 8, 2016.
65. Zimmerman RD, Fleming CA, Lee BC, Saint-Louis LA, Deck MD.
Periventricular hyperintensity as seen by magnetic resonance: prevalence and significance. AJR Am J Roentgenol. 1986;146(3):443-450.
doi:10.2214/ajr.146.3.443.
66. Kim KW, MacFall JR, Payne ME. Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol Psychiatry.
2008;64(4):273-280. doi:10.1016/j.biopsych.2008.03.024.
67. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke.
2001;32(6):1318-1322. http://www.ncbi.nlm.nih.gov/pubmed/11387493.
Accessed March 15, 2016.
57
68. Scheltens P, Erkinjunti T, Leys D, et al. White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol. 1998;39(2):80-89.
http://www.ncbi.nlm.nih.gov/pubmed/9520068. Accessed March 9, 2016.
69. van den Heuvel DMJ, ten Dam VH, de Craen AJM, et al. Measuring longitudinal white matter changes: comparison of a visual rating scale with a volumetric measurement. AJNR Am J Neuroradiol. 2006;27(4):875-878. http://www.ncbi.nlm.nih.gov/pubmed/16611781. Accessed March 15, 2016.
70. Steingart A, Hachinski VC, Lau C, et al. Cognitive and neurologic findings in subjects with diffuse white matter lucencies on computed tomographic scan (leuko-araiosis). Arch Neurol. 1987;44(1):32-35.
http://www.ncbi.nlm.nih.gov/pubmed/3800719. Accessed March 14, 2016.
71. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM.
Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology. 2001;56(11):1539-1545.
http://www.ncbi.nlm.nih.gov/pubmed/11402112. Accessed March 9, 2016.
72. Bennett DA, Gilley DW, Wilson RS, Huckman MS, Fox JH. Clinical correlates of high signal lesions on magnetic resonance imaging in Alzheimer’s disease. J Neurol. 1992;239(4):186-190.
http://www.ncbi.nlm.nih.gov/pubmed/1597684. Accessed March 14, 2016.
73. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM.
Cerebral white matter lesions and depressive symptoms in elderly adults.
Arch Gen Psychiatry. 2000;57(11):1071-1076.
http://www.ncbi.nlm.nih.gov/pubmed/11074873. Accessed March 9, 2016.
74. Tarvonen-Schröder S, Röyttä M, Räihä I, Kurki T, Rajala T, Sourander L.
Clinical features of leuko-araiosis. J Neurol Neurosurg Psychiatry.
1996;60(4):431-436.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1073899&tool=
pmcentrez&rendertype=abstract. Accessed March 9, 2016.
75. Masdeu JC, Wolfson L, Lantos G, et al. Brain white-matter changes in the elderly prone to falling. Arch Neurol. 1989;46(12):1292-1296.
http://www.ncbi.nlm.nih.gov/pubmed/2590013. Accessed March 9, 2016.
76. Whitman GT, Tang Y, Lin A, Baloh RW, Tang T. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction.
Neurology. 2001;57(6):990-994.
http://www.ncbi.nlm.nih.gov/pubmed/11571322. Accessed March 9, 2016.
77. Starr JM, Leaper SA, Murray AD, et al. Brain white matter lesions
detected by magnetic resonance [correction of resosnance] imaging are associated with balance and gait speed. J Neurol Neurosurg Psychiatry.
2003;74(1):94-98.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1738198&tool=
pmcentrez&rendertype=abstract. Accessed March 9, 2016.
78. Baezner H, Blahak C, Poggesi A, et al. Association of gait and balance disorders with age-related white matter changes: the LADIS study.
Neurology. 2008;70(12):935-942.
doi:10.1212/01.wnl.0000305959.46197.e6.
79. Kreisel SH, Blahak C, Bäzner H, et al. Deterioration of gait and balance
58
over time: the effects of age-related white matter change--the LADIS study. Cerebrovasc Dis. 2013;35(6):544-553. doi:10.1159/000350725.
80. Srikanth V, Beare R, Blizzard L, et al. Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study.
Stroke. 2009;40(1):175-180. doi:10.1161/STROKEAHA.108.524355.
81. Corti M-C, Baggio G, Sartori L, et al. White matter lesions and the risk of incident hip fracture in older persons: results from the progetto veneto anziani study. Arch Intern Med. 2007;167(16):1745-1751.
doi:10.1001/archinte.167.16.1745.
82. Soumaré A, Elbaz A, Zhu Y, et al. White matter lesions volume and motor performances in the elderly. Ann Neurol. 2009;65(6):706-715.
doi:10.1002/ana.21674.
83. Blahak C, Baezner H, Pantoni L, et al. Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study. J Neurol Neurosurg Psychiatry. 2009;80(6):608-613.
doi:10.1136/jnnp.2008.154633.
84. Murray ME, Senjem ML, Petersen RC, et al. Functional impact of white matter hyperintensities in cognitively normal elderly subjects. Arch Neurol.
2010;67(11):1379-1385. doi:10.1001/archneurol.2010.280.
85. Kuo H-K, Lipsitz LA. Cerebral white matter changes and geriatric syndromes: is there a link? J Gerontol A Biol Sci Med Sci.
2004;59(8):818-826. http://www.ncbi.nlm.nih.gov/pubmed/15345732.
Accessed February 2, 2016.
86. Piccini P, Pavese N, Canapicchi R, et al. White matter hyperintensities in Parkinson’s disease. Clinical correlations. Arch Neurol. 1995;52(2):191-194. http://www.ncbi.nlm.nih.gov/pubmed/7848130. Accessed March 9, 2016.
87. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson’s disease. A postmortem study. Acta Neuropathol. 2003;105(5):415-419.
doi:10.1007/s00401-003-0676-3.
88. Bohnen NI, Müller MLTM, Zarzhevsky N, et al. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson’s disease. Brain.
2011;134(Pt 8):2358-2365. doi:10.1093/brain/awr139.
89. Sohn YH, Kim JS. The influence of white matter hyperintensities on the clinical features of Parkinson’s disease. Yonsei Med J. 1998;39(1):50-55.
doi:10.3349/ymj.1998.39.1.50.
90. Ebersbach G, Sojer M, Müller J, Ransmayr G, Wenning G, Poewe W.
[Dysequilibrium in idiopathic Parkinson disease. The effect of cerebrovascular comorbidity]. Nervenarzt. 2002;73(2):162-165.
http://www.ncbi.nlm.nih.gov/pubmed/11975093. Accessed March 28, 2016.
91. Kotagal V, Albin RL, Müller MLTM, Koeppe RA, Frey KA, Bohnen NI.
Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology. 2014;82(17):1514-1520.
doi:10.1212/WNL.0000000000000356.
92. Sartor J, Bettecken K, Bernhard FP, et al. White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and
59
Parkinson’s Disease. Front Aging Neurosci. 2017;9:213.
doi:10.3389/fnagi.2017.00213.
93. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1014720&tool=
pmcentrez&rendertype=abstract. Accessed February 15, 2015.
94. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing.
1997;26(5):353-357. http://www.ncbi.nlm.nih.gov/pubmed/9351479.
Accessed March 30, 2016.
95. Beck, A. T., Steer, R. A., Brown GK. Beck-Depressions-Inventar (2.
Auflage). 2006.
96. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol.
1982;37(3):323-329. http://www.ncbi.nlm.nih.gov/pubmed/7069156.
Accessed February 17, 2016.
97. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170. doi:10.1002/mds.22340.
98. Probst CC, Winter LM, Möller B, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol.
2014;261(5):936-942. doi:10.1007/s00415-014-7299-6.
99. Rios Romenets S, Wolfson C, Galatas C, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord.
2012;18(1):54-58. doi:10.1016/j.parkreldis.2011.08.013.
100. Johns MW. Daytime Sleepiness, Snoring, and Obstructive Sleep Apnea:
The Epworth Sleepiness Scale. Chest. 1993;103(1):30-36.
doi:10.1378/chest.103.1.30.
101. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res. 1982;17(1):37-49. doi:10.1016/0022-3956(82)90033-4.
102. Coyne KS, Matza LS, Kopp Z, Abrams P. The Validation of the Patient Perception of Bladder Condition (PPBC): A Single-Item Global Measure for Patients with Overactive Bladder. Eur Urol. 2006;49(6):1079-1086.
doi:10.1016/j.eururo.2006.01.007.
103. Timmermans L, Falez F, Mélot C, Wespes E. Validation of use of the International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI-SF) for impairment rating: A transversal retrospective study of 120 patients. Neurourol Urodyn.
2013;32(7):974-979. doi:10.1002/nau.22363.
104. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and
recommendations. Mov Disord. 2004;19(9):1020-1028.
doi:10.1002/mds.20213.
60
105. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer’s disease (CERAD) clinical and
neuropsychological assessment of Alzheimer’s disease.
Psychopharmacol Bull. 1988;24(4):641-652.
http://www.ncbi.nlm.nih.gov/pubmed/3249766. Accessed March 15, 2016.
106. Aster, M. v., Neubauer, A. Horn R. Wechsler Intelligenztest Für Erwachsene. (Pearson, ed.).; 2006.
107. Sturm, W., Willmes, K. Horn W. Leistungsprüfsystem Für 50-90jährige (LPS 50+). Göttingen: Hogrefe Verlag; 1993.
108. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
doi:10.1111/j.1532-5415.2005.53221.x.
109. McDermott MP, Jankovic J, Carter J, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson’s disease. The
Parkinson Study Group. Arch Neurol. 1995;52(6):565-570.
http://www.ncbi.nlm.nih.gov/pubmed/7763203. Accessed March 28, 2016.
110. Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I.
Test-retest reliability of the unified Parkinson’s disease rating scale in patients with early Parkinson’s disease: results from a multicenter clinical trial. Mov Disord. 2002;17(4):758-763. doi:10.1002/mds.10011.
111. Bernard A. Gibt es den inflammatorischen Endophänotyp bei der Parkinson-Erkrankung? Assoziation von Genotyp,
Entzündungsparametern und dem Parkinson-Phänotyp. 2016.
112. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease.
Mov Disord. 2010;25(15):2649-2653. doi:10.1002/mds.23429.
113. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C. Development of a common outcome data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. J Am Geriatr Soc. 2005;53(9):1618-1622. doi:10.1111/j.1532-5415.2005.53455.x.
114. Urban D, Mayerl J. Regressionsanalyse: Theorie, Technik Und
Anwendung. 2nd ed. Wiesbaden: VS Verlag für Sozialwissenschaften;
2006.
115. Lee RSC, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord. 2012;140(2):113-124. doi:10.1016/j.jad.2011.10.023.
116. Ng A, Chander RJ, Tan LCS, Kandiah N. Influence of depression in mild Parkinson’s disease on longitudinal motor and cognitive function.
Parkinsonism Relat Disord. 2015;21(9):1056-1060.
doi:10.1016/j.parkreldis.2015.06.014.
117. Aronson MK, Ooi WL, Geva DL, Masur D, Blau A, Frishman W.
Dementia. Age-dependent incidence, prevalence, and mortality in the old old. Arch Intern Med. 1991;151(5):989-992.
http://www.ncbi.nlm.nih.gov/pubmed/2025148. Accessed May 11, 2016.
118. Habes M, Erus G, Toledo JB, et al. White matter hyperintensities and imaging patterns of brain ageing in the general population. Brain.
February 2016. doi:10.1093/brain/aww008.